Cellectis (NASDAQ: CLLS) reported Q2 EPS of ($0.28), $0.01 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $9.5 million versus the consensus estimate of $3.47 million.

For earnings history and earnings-related data on Cellectis (CLLS) click here.